



Patient Name : Mr. SURESH KACHARU SHIROSE	Collected : 16/May/2025 04:08PM
Age/Gender : 45 Years/M	Received : 17/May/2025 10:28AM
UHID/MR No : ABSC.0000004103	Reported : 21/May/2025 11:53AM
Visit ID : ABSC4104	Status : Final Report
Ref Doctor : Dr.Dr. Sreekanth Reddy	Client Name : 4BASECARE PRECISION HEALTH PVT LTD
Case Id : H-11723/25	Ward Name :

**IMMUNOHISTOCHEMISTRY REPORT**  
**PDL1- IHC**

<b>Clinical History:</b>	Case of carcinoma thyroid in bone
--------------------------	-----------------------------------

<b>Specimen:</b>	Slides for immunohistochemistry - PDL1 by SP263
------------------	---

<b>Macroscopic findings:</b>	Received by Mr. Anjan Received three unstained coated slides labelled as 56568 Slides identified based on the label and previous copy
------------------------------	---

<b>Microscopic description:</b>	<b>Immunohistochemistry:</b> Immunohistochemistry done on slide - 56568  Percentage of tumor cells with membrane staining for PD-L1: <1% Number of PD-L1 staining cells (Tumor cells + Immune cells): 1 Total number of viable tumor cells: 275 Combined proportion score (CPS): 0.36
---------------------------------	---

<b>Impression:</b>	No PDL1 expression seen.
--------------------	--------------------------

Comments:	<b>PDL1 interpretation:</b>			
	Clone: Roche SP263			
	Site	Tumor Cell score (TC)	Combined Proportion Score (CPS)	Result
	Non-Small Cell Lung Cancer <sup>1, 2</sup>	PD-L1 Expression Level < 1%	--	No PDL1 expression (Negative)
		PD-L1 Expression Level ≥ 1%	--	PDL1 expression (Positive)
	Urothelial Carcinoma <sup>1</sup>	• ≥ 25% of tumor cells exhibit membrane staining; or, • ICP > 1% and IC+ ≥ 25%; or, • ICP = 1% and IC+ = 100%		High PDL1 expression
		• None of the criteria for PD-L1 High Status are met.		Low / Negative PD-L1 expression
	Cervical Carcinoma <sup>4</sup>	--	< 1	No PDL1 expression
--		≥ 1	PDL1 expression	



Patient Name	: Mr. SURESH KACHARU SHIROSE	Collected	: 16/May/2025 04:08PM
Age/Gender	: 45 Years/M	Received	: 17/May/2025 10:28AM
UHID/MR No	: ABSC.0000004103	Reported	: 21/May/2025 11:53AM
Visit ID	: ABSC4104	Status	: Final Report
Ref Doctor	: Dr.Dr. Sreekanth Reddy	Client Name	: 4BASECARE PRECISION HEALTH PVT LTD
Case Id	: H-11723/25	Ward Name	:

**IMMUNOHISTOCHEMISTRY REPORT**  
**PDL1- IHC**

Head and Neck	--	< 1	No PDL1 expression
Carcinoma <sup>2,3</sup>	--	≥ 1	PDL1 expression
Esophageal	--	< 10	No PDL1 expression
Squamous Cell	--	≥ 10	PDL1 expression
Carcinoma <sup>4</sup>	--	≥ 10	PDL1 expression
Triple Negative	--	< 10	No PDL1 expression
Breast Carcinoma	--	≥ 10	PDL1 expression
(TNBC) <sup>4</sup>	--	≥ 10	PDL1 expression
Other tumor types <sup>4</sup>	< 1%	< 1%	No PDL1 expression
	1 - 49%	1 - 49%	PDL1 expression
	≥ 50%	≥ 50%	High PDL1 expression

**Note:**

- o PDL1 IHC (clone Ventana SP 263) is an FDA approved companion diagnostic for selecting patients for immunotherapy.
- o This assay is performed on Ventana BenchMark Ultra.
- o Tumour cells and mononuclear inflammatory cells (within tumour nests or adjacent supporting stroma) with partial or complete linear membrane staining of at least 1+ intensity are scored as positive. The combined positive score is estimated by manual quantification.
- o The test is performed if ≥ 100 tumour cells are present.
- o Certain tissue processing factors, such as decalcification, formalin fixation time outside an acceptable range (< 3 hours), prolonged time to fixation and use of tissue from blocks that are 6 months or older, can affect PDL1 staining / expression and results should be interpreted with caution in such instances.
- o This assay is not validated for decalcified specimens.
- o All controls show appropriate reactivity.

**Reference:**

1. Ventana PD-L1 SP263 Interpretation Manual for NSCLC and Urothelial Carcinoma.
2. Marletta S, Fusco N, Munari E et al. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. J Pers Med 2022 Jun 29;12(7):1073. doi: 10.3390/jpm12071073.
3. Pai T, Aiyer HM, Kulkarni B, Vidya MN, Patne S, Sewlikar S, et al. Role of PD-L1 SP263 Assay in Cancer Immunotherapy: A Comprehensive Review. J Cancer Immunol. 2024;6(2):77-91.
4. Extrapolated from 22c3 interpretation guidelines – To be interpreted with caution with clinical correlation.

Slides enclosed

**Note:**

\* This report is not valid for partial / divided specimens. Slides and blocks will be issued after 2 days of written request. Reporting is done on Digital pathology images (WSI) & / or Microscopy.



Patient Name	: Mr. SURESH KACHARU SHIROSE	Collected	: 16/May/2025 04:08PM
Age/Gender	: 45 Years/M	Received	: 17/May/2025 10:28AM
UHID/MR No	: ABSC.0000004103	Reported	: 21/May/2025 11:53AM
Visit ID	: ABSC4104	Status	: Final Report
Ref Doctor	: Dr.Dr. Sreekanth Reddy	Client Name	: 4BASECARE PRECISION HEALTH PVT LTD
Case Id	: H-11723/25	Ward Name	:

**IMMUNOHISTOCHEMISTRY REPORT**  
**PDL1- IHC**

**Digital slide images are available on request.**

Entered By :

Verified By:

Approved By :

**Dr. Ojal Usgaonkar**

**Dr Veena R., MD(Pathology)**

DNB Resident

KMC No.: 44080

Sunitha Chikerre

KMC No.: 5104

Sr Consultant Pathologist

\*\*\* End Of Report. \*\*\*



SIN No:IH00053391